Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies

Acta Neurologica Scandinavica

Volumn 115, Issue 3, 2007, Pages 137-146

  Szczuciński, Adam ^a   Losy, Jacek ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Chemokine receptors; Chemokines; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; BETA1A INTERFERON; CHEMOKINE; CHEMOKINE CCL4; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CLADRIBINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MARAVIROC; METHYLPREDNISOLONE; MLN 1202; MLN 3897; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; T 487; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; DEMYELINATION; DENDRITIC CELL; DRUG MECHANISM; DRUG TARGETING; EOSINOPHIL; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; IMMUNOMODULATION; LEUKOCYTE MIGRATION; LIGAND BINDING; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE;

CHEMOKINES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE;

EID: 33846856922     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00749.x     Document Type: Review

References (106)

1. COMPSTON A, COLES A. Multiple sclerosis. Lancet 2002;359:1221-31.
2. NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WIENSHENKER BG. Multiple sclerosis. N Engl J Med 2000;13:938-52.
3. HICKEY W. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol 1999;98:37-44.
4. MCDONALD WI, COMPSTON A, EDAN G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
5. LUCCHINETTI C, BRUCK W, RODRIGUEZ M, LASSMANN H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-74.
6. LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
7. LASSMANN H. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002;104:168-71.
8. BARNETT MH, PRINEAS JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68.
9. MATUTE C, PEREZ-CERDA F. Multiple sclerosis: novel perspectives on newly forming lesions. Trends Neurosci 2005;28:173-5.
10. RANSOHOFF RM. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J Neuroimmunol 1999;98:57-68.
11. LOSY J, NIEZGODA A, WENDER M. Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions. J Neuroimmunol 1999;99:169-72.
12. SELLEBJERG F, SØRENSEN TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61:347-55.
13. OPDENAKKER G, NELISSEN I, VAN DAMME J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003;2:747-56.
14. IMITOLA J, CHITNIS T, KHOURY SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005;106:163- 77.
15. LASSMANN H, RANSOHOFF RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004;25:132-7.
16. SEGAL BM. CBS chemokines, cytokines, and dendritic cells in autoimmune demyelination. J Neurol Sci 2005;228:210-4.
17. KIVISÄKK P, TREBST C, ECKSTEIN DJ, KERZA-KWIATECKI AP, RANSOHOFF RM. Chemokine-based therapies for MS: how do we get there from here? Trends Immunol 2001;22:591-3.
18. BAGGIOLINI M. Chemokines and leukocyte traffic. Nature 1998;392:565-8.
19. LUSTER AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;7:436-45.
20. UBOGU EE, COSSOY MB, RANSOHOFF RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006;27:48-55.
21. CHARO IF, RANSOHOFF RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21.
22. CARTIER L, HARTLEY O, DUBOIS-DAUPHIN M, KRAUSE KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Rev 2005;48:16-42.
23. GODESSART N, KUNKEL S. Chemokines in autoimmune disease. Curr Opin Immunol 2001;13:670-5.
24. BIBER K, ZUURMAN MW, DIJKSTRA IM, BODDEKE HWGM. Chemokines in the brain: neuroimmunology and beyond. Curr Opin Pharmacol 2002;2:63-8.
25. ZLOTNIK A, YOSHIE O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7.
26. MURPHY PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002;54:227-9.
27. PETKOVIC V, MOGHINI C, PAOLETTI S, UGUCCIONI M, GERBER B. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. J Biol Chem 2004;279:23357-63.
28. LOETSCHER P, PELLEGRINO A, GONG JH et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276:2986-91.
29. ZHANG GX, BAKER CM, KOLSON DL, ROSTAMI AM. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler 2000;6:3-13.
30. GLABINSKI AR, TANI M, STRIETER RM, TUOHY VK, RANSOHOFF RM. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997;150:617-30.
31. KARPUS WJ, KENNEDY KJ. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997;62:681-7.
32. KARPUS W, RANSOHOFF R. Commentary: Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol 1998;161:2667-71.
33. HUANG D, WANG J, KIVISÄKK P, ROLLINS BJ, RANSOHOFF RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001;93:713-26.
34. IZIKSON L, KLEIN RS, CHARO IF, WEINER HL, LUSTER AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000;192:1075-80.
35. FIFE BT, HUNAGLKE GB, KUZIEL WA, KARPUS WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000;192:899-905.
36. GAUPP S, PITT D, KUZIEL WA, CANNELLA B, RAINE C. Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am J Pathol 2003;162:139-50.
37. ROTTMAN JB, SLAVIN AJ, SILVA R, WEINER HL, GERARD CG, HANCOCK WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000;30:2372-7.
38. KARPUS WJ, LUKACS NW, MCRAE BL, STRIETER RM, KUNKEL SL, MILLER SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-10.
39. MATSUI W, WEAVER J, PROUDFOOT AE et al. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol 2002;128:16-22.
40. FIFE BT, KENNEDY KJ, PANAGUA MC et al. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001;166:7617-24.
41. NARUMI S, KABURAKI T, YONEYAMA H, IWAMURA H, KOBAYASHI Y, MATSUSHIMA K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2002;32:1784-91.
42. KLEIN RS, IZIKSON L, MEANS T et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004;172:550-9.
43. TSUNODA I, LANE TE, BLACKETT J, FUJINAMI RS. Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. Mult Scler 2004;10:26-34.
44. FUKUMOTO N, SHIMAOKA T, FUJIMURA H et al. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phophatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 2004;173:1620-7.
45. CARVALHO DOS SANTOS A, BARSANTE MM, ARANTES RME, BERNARD CCA, TEIXEIRA MM, Carvalho-Tavares J. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis - an intravital microscopy study. J Neuroimmunol 2005;162:122-9.
46. TREBST C, RANSOHOFF RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis. Arch Neurol 2001;58:1975-80.
47. PASHENKOV M, SÖDERSTRÖM M, LINK H. Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. J Neuroimmunol 2003;135:154- 60.
48. KASTENBAUER S, KOEDEL U, WICK M, KIESEIER BC, HARTUNG HP, PFISTER HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003;137:210-7.
49. KIVISÄKK P, MAHAD DJ, CALLAHAN MK et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004;55:627-38.
50. SØRENSEN TL, TREBST C, KIVISÄKK P et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002;127:59-68.
51. SØRENSEN T, TANI M, JENSEN J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
52. MISU T, ONODERA H, FUJIHARA K et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neutoimmunol 2001;114:207-12.
53. SØRENSEN TL, SELLEBJERG F, JENSEN CV, STRIETER RM, RANSOHOFF RM. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001;8:665-72.
54. FRANCIOTTA D, MARTINO G, ZARDINI E et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-8.
55. BALASHOV KE, ROTTMAN JB, WEINER HL, HANCOCK WW. CCR5(+) and CCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-8.
56. SIMPSON JE, REZAIE P, NEWCOMBE J, CUZNER ML, MALE D, WOODROOFE MN. Expression of the β-chemokine receptor CCR2, CCR3, CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000;108:192-200.
57. MAHAD DJ, LAWRY J, HOWELL SJL, WOODROOFE MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler 2003;9:189-98.
58. SINDERN E, PATZOLD T, OSSEGE LM, GISEVIUS A, MALIN JP. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2002;131:186-90.
59. WANG HY, MATSUI M, ARAYA S, ONAI N, MATSUSHIMA K, SAIDA T. Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis. J Neuroimmunol 2002;133:184-92.
60. NAKAJIMA H, FUKUDA K, DOI Y et al. Expression of Th1/ Th2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur Neurol 2004;52:162-8.
61. SØRENSEN TL. Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease? Curr Neurovasc Res 2004;1:183-90.
62. SIMPSON JE, NEWCOMBE J, CUZNER ML, WOODROOFE MN. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998;84:238-49.
63. MCMANUS C, BERMAN JW, BRETT FM, STAUNTON H, FARRELL M, BROSNAN CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998;86:20-9.
64. TELESHOVA N, PASHENKOV M, HUANG YM et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 2002;249:723-9.
65. MIYAGISHI R, KIKUCHI S, FUKAZAWA T, TASHIRO K. Macrophage inflammatory protein-1alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1995;129:223-7.
66. SINDERN E, NIEDERKINHAUS Y, HENSCHEL M, OSSEGE LM, PATZOLD T, MALIN JP. Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2001;104:88-91.
67. BARTOSIK-PSUJEK H, STELMASIAK Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005;12:49-54.
68. EIKELENBOOM MJ, KILLESTEIN J, IZEBOUD T et al. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J Neuroimmunol 2002;133:225-32.
69. ACHIRON A. Chemokine polymorphisms: candidates for MS susceptibility and disease course. Int MS J 2004;11:71-7.
70. BENNETTS BH, TEUTSCH SM, BUHLER MM, HEARD RN, STEWART GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997;58:52-9.
71. SELLEBJERG F, MADSEN HO, JENSEN CV, JENSEN J, GARRED P. CCR5 delta 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000;102:98- 106.
72. KANTOR R, BAKHANASHVILI M, ACHIRON A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 2003;61:238-40.
73. SILVERSIDES JA, HEGGARTY SV, MCDONELL GV, HAWKINS SA, GRAHAM CA. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004;10:149-52.
74. GADE-ANDAVOLU R, COMINGS DE, MACMURRAY J et al. Association of CCR5 delta 32 deletion with early death in multiple sclerosis. Genet Med 2004;6:126-31.
75. GADE-ANDAVOLU R, COMINGS DE, MACMURRAY J et al. RANTES: a genetic risk marker for multiple sclerosis. Mult Scler 2004;10:536-9.
76. VAN DER VOORN P, TEKSTRA J, BEELEN RH, TENSEN CP, VAN DER VALK P, DE GROOT CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999;154:45-51.
77. SØRENSEN TL, SELLEBJERG F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001;57:1371-6.
78. NARIKAWA K, MISU T, FUJIHARA K, NAKASHIMA I, SATO S, ITOJAMA Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004;149:182-6.
79. MAHAD DJ, RANSOHOFF RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003;15:23-32.
80. SØRENSEN TL, RANSOHOFF RM, STRIETER RM, SELLEBJERG F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol 2004;11:445-9.
81. MAHAD D, CALLAHAN MK, WILLIAMS KA et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006;129:212-23.
82. KRUMBHOLZ M, THEIL D, CEPOK S et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200- 11.
83. OMARI K, JOHN GR, SEALFON SC, RAINE CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005;128:1003-15.
84. JALONEN TO, PULKKINEN K, UKKONEN M, SAARELA M, ELOVAARA I. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. J Neurol 2002;249:576-83.
85. MAHAD DJ, HOWELL SJL, WOODROOFE MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:498-502.
86. SCARPINI E, GALIMBERTI D, BARON P et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002;195:41-46.
87. MARTINEZ-CACERES EM, ESPEJO C, BRIEVA L et al. Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult Scler 2002;8:390-5.
88. COMABELLA M, IMITOLA J, WEINER HL, KHOURY SJ. Interferon-β treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol 2002;126:205-12.
89. IARLORI C, REALE M, LUGARESI A et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b. J Neuroimmunol 2000;107:100- 7.
90. SZCZUCIŃSKI A, LOSY J. Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis. Folia Neuropathol 2004;42:15-8.
91. BARTOSIK-PSUJEK H, STELMASIAK Z. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse. Eur Neurol 2004;52:237-41.
92. ELOVAARA I, KUUSISTO H, PAALAVUO R et al. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol Scand 2006;113:163-6.
93. BARTOSIK-PSUJEK H, BELNIAK E, MITOSEK-SZEWCZYK K, DOBOSZ B, STELMASIAK Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 2004;109:390-2.
94. LUND BT, ASHIKIAN N, TA HQ et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 2004;155:161-71.
95. IARLORI C, REALE M, DE LUCA G et al. Interferon β-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J Neuroimmunol 2002;123:170-9.
96. JOHNSON Z, SCHWARZ M, POWER CA, WELLS TNC, PROUFOOT AEI. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol 2005;26:268-74.
97. TERRICABRAS E, BENJAMIM C, GODESSART N. Drug discovery and chemokine receptor antagonists: eppur si muove! Autoimmun Rev 2004;3:550-6.
98. FOX RJ, RANSOHOFF RM. New directions in MS therapeutics: vehicles of hope. Trends Immunol 2004;25:632-6.
99. HORUK R. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 2003;29:369-75.
100. LIANG M, MALLARI C, ROSSER M et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-8.
101. RIBEIRO S, HORUK R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005;107:44-58.
102. VAN OOSTEN BW, BARKHOF F, BORINGA JB et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
103. SICOTTE NL, VOSKUHL RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
104. KLEINSCHMIDT-DEMASTERS BK, TYLER KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
105. LANGER-GOULD A, ATLAS SW, GREEN AJ, BOLLEN AW, PELLETIER D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
106. ENGELHARDT B, BRISKIN MJ. Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol 2005;35:2268-73.